Inhibikase Therapeutics
IKT
48 hedge funds and large institutions have $106M invested in Inhibikase Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 23 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
4.1% more ownership
Funds ownership: 69.23% → 73.33% (+4.1%)
2% more funds holding
Funds holding: 47 → 48 (+1)
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $113M → $106M (-$6.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.51M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.45M |
| 3 |
Blackstone Inc
New York
|
+$1.11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$736K |
| 5 |
State Street
Boston,
Massachusetts
|
+$697K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$965K |
| 3 |
Goldman Sachs
New York
|
-$364K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$355K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$340K |
IKT Hedge Fund Activity: Q2 2025 in Review
48 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2025, worth a combined $106M — down 5.7% from $113M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new IKT positions and 23 closed out — a net gain of 1 holder — while 11 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $4.51M. The largest seller was Millennium Management, exiting entirely with an estimated $2M sold.
- 48 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2025, up from 47 in Q1 2025.
- Funds reported $106M of Inhibikase Therapeutics stock for Q2 2025, down 5.7% quarter-over-quarter.
- 24 funds opened new Inhibikase Therapeutics positions in Q2 2025 and 23 closed out, a net change of +1 holder.
- The largest Inhibikase Therapeutics buyer in Q2 2025 was BlackRock, an estimated $4.51M added.
- The largest Inhibikase Therapeutics seller in Q2 2025 was Millennium Management, an estimated $2M sold.
Based on aggregated 13F filings for Q2 2025.